Global Organ Transplant
Immunosuppressant Drugs Market: Regional Analysis
On the basis of region, the
global Organ
Transplant Immunosuppressant Drugs Market is segmented into North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa.
Increasing cases of kidney
disorders in the U.S. is expected to propel growth of the organ transplant
immunosuppressant drugs market in North America. For instance, according to the
United Network for Organ Sharing (UNOS), in 2016, 19,061 kidney transplants
were performed in the U.S. compared to 17,878 kidney transplants in 2015.
Therefore, the number of kidney transplants increased by 6.6% in 2016.
Immunosuppressant is a drug used
to suppress immune responses through various mechanisms. It is used in organ
transplant to prevent the body from recognizing or attacking the transplanted
organ. Immunosuppressant drugs can act by preventing and treating
graft-versus-host disease and can minimize destruction of affected tissues in
autoimmune and inflammatory diseases. There are two types of immunosuppressant
drugs: induction drugs and maintenance drugs. Induction drugs are antirejection
medicines that are used during the transplant, whereas maintenance drugs are
antirejection medicines intended to use for long term.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2495
Global Organ Transplant Immunosuppressant
Drugs Market: Drivers
Increasing number of patients
that require organ transplants is expected to boost the organ transplant
immunosuppressant drugs market. For instance, according to the U.S. Government
Information on Organ Donation and Transplantation, U.S. Department of Health
& Human Services, in 2017, 34770 organ transplants were performed in the
U.S. and over 114000 patients were in need for organ transplantation.
Moreover, increasing approval for
new products is expected to boost the organ transplant immunosuppressant drugs
market growth. For instance, in April 2017, the U.S. Food and Drug
Administration (FDA) approved Thymoglobulin (anti-thymocyte globulin (rabbit)
produced by Sanofi. Thymoglobulin is intended to use in conjunction with
concomitant immunosuppression in the prophylaxis and prevention of acute
rejection in patients receiving a kidney transplant.
However, decreasing number of
organ transplantation due to shortage of organs may hinder growth for the organ
transplant immunosuppressant drugs market. For instance, according to National
Center for Biotechnology Information (NCBI), in 2015, only 30,973 organ
transplants from 15,064 donors were performed in the U.S., while over 121,000
candidates were in need for organ transplantation.
Moreover, according to a report
by Organ Donation and Transplantation Activity Report, the number of organ
transplants decreased from 4,655 in 2013/14 to 4,431 in 2014/15 in the U.K.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/organ-transplant-immunosuppressant-drugs-market-2495
Moreover, increasing number of
pipeline studies to develop drugs for organ transplant rejection is expected to
contribute to growth of the market. For instance, in November 2018, Temple
University, in collaboration with Veloxis Pharmaceuticals, initiated phase 4
clinical trial for Tacrolimus Extended Release Oral Tablet to evaluate dosing
strategies for de novo once-daily extended release tacrolimus (LCPT) in kidney
transplant recipients. The study is expected to be completed by August 2019.
Europe is expected to witness
significant growth in the market over the forecast period. The growth is
attributed to increasing product launch by key players in this region. For
instance, in 2013, Roche Group launched two new highly-sensitive therapeutic
drug monitoring tests for immunosuppressant medicines – tacrolimus and
cyclosporine worldwide (except U.S.). Therapeutic monitoring for
immunosuppressive drugs is a major part of transplant medicine and is crucial
for maintaining the health of patients with organ transplantation for longer
period.
Key player operating in the organ
transplant immunosuppressant drugs market include, Astellas Pharma, Genzyme
Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG,
Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC,
Leo Pharma As, Glenmark Pharmaceuticals Ltd., Veloxis Pharmaceuticals Inc., Dr.
Reddy’s Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd.,
and Hoffman La Roche.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2495
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment